Department of Neuroscience, Mayo Clinic, Jacksonville, FL, 32224, USA.
Division of Clinical Trials and Biostatistics, Department of Quantitative Health Sciences, Mayo Clinic, Jacksonville, FL, 32224, USA.
Acta Neuropathol Commun. 2024 Feb 9;12(1):25. doi: 10.1186/s40478-024-01731-0.
Alzheimer's disease (AD), characterized by the deposition of amyloid-β (Aβ) in senile plaques and neurofibrillary tangles of phosphorylated tau (pTau), is increasingly recognized as a complex disease with multiple pathologies. AD sometimes pathologically overlaps with age-related tauopathies such as four repeat (4R)-tau predominant argyrophilic grain disease (AGD). While AGD is often detected with AD pathology, the contribution of APOE4 to AGD risk is not clear despite its robust effects on AD pathogenesis. Specifically, how APOE genotype influences Aβ and tau pathology in co-occurring AGD and AD has not been fully understood. Using postmortem brain samples (N = 353) from a neuropathologically defined cohort comprising of cases with AD and/or AGD pathology built to best represent different APOE genotypes, we measured the amounts of major AD-related molecules, including Aβ40, Aβ42, apolipoprotein E (apoE), total tau (tTau), and pTau181, in the temporal cortex. The presence of tau lesions characteristic of AD (AD-tau) was correlated with cognitive decline based on Mini-Mental State Examination (MMSE) scores, while the presence of AGD tau lesions (AGD-tau) was not. Interestingly, while APOE4 increased the risk of AD-tau pathology, it did not increase the risk of AGD-tau pathology. Although APOE4 was significantly associated with higher levels of insoluble Aβ40, Aβ42, apoE, and pTau181, the APOE4 effect was no longer detected in the presence of AGD-tau. We also found that co-occurrence of AGD with AD was associated with lower insoluble Aβ42 and pTau181 levels. Overall, our findings suggest that different patterns of Aβ, tau, and apoE accumulation mediate the development of AD-tau and AGD-tau pathology, which is affected by APOE genotype.
阿尔茨海默病(AD)的特征是淀粉样β(Aβ)在老年斑和磷酸化 tau(pTau)的神经原纤维缠结中的沉积,它越来越被认为是一种具有多种病理学的复杂疾病。AD 有时与年龄相关的 tau 病重叠,例如四重复(4R)-tau 为主的颗粒状银染病(AGD)。虽然 AGD 常与 AD 病理学同时检测到,但尽管 APOE4 对 AD 发病机制有很强的影响,但它对 AGD 风险的贡献尚不清楚。具体来说,APOE 基因型如何影响同时发生的 AGD 和 AD 中的 Aβ和 tau 病理学尚未完全理解。使用来自一个神经病理学定义的队列的死后脑样本(N=353),该队列由具有 AD 和/或 AGD 病理学的病例组成,以最好地代表不同的 APOE 基因型,我们测量了颞叶皮质中主要与 AD 相关的分子的含量,包括 Aβ40、Aβ42、载脂蛋白 E(apoE)、总 tau(tTau)和 pTau181。具有 AD tau 病变特征的存在(AD-tau)与基于 Mini-Mental State Examination(MMSE)评分的认知能力下降相关,而 AGD tau 病变的存在(AGD-tau)则没有。有趣的是,虽然 APOE4 增加了 AD-tau 病理学的风险,但它并没有增加 AGD-tau 病理学的风险。尽管 APOE4 与不溶性 Aβ40、Aβ42、apoE 和 pTau181 的水平显著相关,但在存在 AGD-tau 的情况下,APOE4 的作用不再被检测到。我们还发现,AGD 与 AD 的共存与较低的不溶性 Aβ42 和 pTau181 水平有关。总的来说,我们的发现表明,不同模式的 Aβ、tau 和 apoE 积累介导了 AD-tau 和 AGD-tau 病理学的发展,而这又受到 APOE 基因型的影响。